UNSPSC 51292019: Citalopram hydrobromide

This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C20H21FN2O.BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I1E9D14F36, chemically known as 1,3-dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile but more generally known as citalopram hydrobromide, which bears US NIH Compound Identifier 2771.

UNSPSC 51292019 Citalopram hydrobromide is a Commodity code that captures pharmaceutical active ingredients and finished-form medications procured by state and local health agencies, but recent state and local opportunities tagged under this code reflect broader pharmaceutical supply activity rather than citalopram specifically—including naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical contracting through cooperative purchasing vehicles. State and local issuing bodies acquiring under this code span county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida; Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) have all posted solicitations recently tagged to this code, indicating that state agencies and county-level health operations drive the bulk of visible activity.

Recent procurement activity concentrates in Florida and Texas, with multistate cooperative purchasing extending coverage to Minnesota and Oregon. Seminole County released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; responses were due July 26, 2023 (the solicitation displays a date anomaly that suggests the source record may contain legacy data). The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative focused on direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP, administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, with a March 26, 2026 deadline, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities; the contract term runs two years beginning July 1, 2026, with a 3 percent administrative fee and performance penalties ranging from $200 to $1,500 per violation.